Developer of modulating biotherapeutics to address cancer and autoimmune diseases. It has AbiLeap discovery engine that combines continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies across cancer and autoimmune applications. The pipeline includes Leap 1121 for auti-immune disease, Leap 1009 and 1030 for solid tumors.
← All startups
Ability
SeedDeveloper of modulating biotherapeutics to address cancer and autoimmune diseases. It has AbiLeap discovery engine that combines continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies across cancer and autoimmune applications. The pipeline includes Leap 1121 for auti-immune disease, Leap 1009 and 1030 for solid tumors.
About
Institutional investors
AmplitudeFonds de solidarite FTQCharles River LaboratoriesAlexandriaPage One VenturesInvest QuebecTheodorus
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.